About the Authors

Eric P. Nagele

Contributed equally to this work with: Eric P. Nagele, Min Han

Affiliations Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, Durin Technologies, Inc., New Brunswick, New Jersey, United States of America

Min Han

Contributed equally to this work with: Eric P. Nagele, Min Han

Affiliations Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences at the School of Osteopathic Medicine, Stratford, New Jersey, United States of America

Nimish K. Acharya

Affiliations Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences at the School of Osteopathic Medicine, Stratford, New Jersey, United States of America

Cassandra DeMarshall

Affiliations Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences at the School of Osteopathic Medicine, Stratford, New Jersey, United States of America

Mary C. Kosciuk

Affiliation Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America

Robert G. Nagele

nagelero@umdnj.edu

Affiliation Biomarker Discovery Center, New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America

Competing Interests

RGN is a stockholder in Durin Technologies, Inc., a small biotech company that is developing disease diagnostics using autoantibodies as biomarkers, and has filed patents on this technology. EPN is a paid consultant of Durin Technologies. This study was funded by the Foundation Venture Capital Group. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: EPN MH RGN. Performed the experiments: EPN MH NKA CD MCK. Analyzed the data: EPN MH NKA CD RGN. Contributed reagents/materials/analysis tools: RGN. Wrote the paper: EPN MH NKA RGN.